Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06875609 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ctDNA in Cutaneous Squamous Cell Carcinoma

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 1, 2025 to Mar 24, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.
Trial Details
NCT Number NCT06875609
Lead Sponsor Massachusetts Eye and Ear Infirmary
Collaborators: Haystack Oncology, Inc., Massachusetts General Hospital
Conditions
(from sponsor)		 Cutaneous Squamous Cell Carcinoma
Related terms Neoplasm, Residual, Skin Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov